• Crossject secured USD 4.7 million in additional BARDA funding for ZEPIZURE pediatric development, extending the contract through June 21, 2030.
• Total BARDA support for ZEPIZURE rises to USD 48 million.
• Adult Emergency Use Authorization filing remains unchanged, with no impact on the scope or data package.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crossject SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609231300OMX_____CNEWS_EN_GNW1001274246_en) on September 23, 2026, and is solely responsible for the information contained therein.